13F Holdings
中文EN

PEN Penumbra Inc

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1321732 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.0%
TTM net income YoY-4.3%
TTM EPS YoY-5.3%
Revenue 3-yr CAGR16.2%
Net income 3-yr CAGR56.9%

Margins

Gross margin68.0%
Operating margin12.1%
Net margin10.1%
FCF margin12.8%
EBITDA margin13.4%

Returns

ROE10.7%
ROA8.3%
ROIC (approx.)12.1%
Asset turnover0.83x

Leverage & solvency

Liabilities / assets21.8%
Debt / equity0.00x
Current ratio5.89x
Interest coverage149.48x

Cash quality & payout

Operating cash flow / net income1.66x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue3.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.40B$1.19B$1.06B$847.13M$747.59M
Cost of revenue$461.23M$439.62M$375.88M$311.93M$272.21M
Gross profit$942.44M$755.00M$682.64M$535.21M$475.38M
R&D expense$89.77M$94.78M$84.42M$79.41M$104.55M
SG&A expense$663.42M$573.99M$506.45M$449.72M$378.33M
Operating income$189.25M$9.28M$73.55M$6.08M-$7.50M
Interest expense$1.31M$1.42M$1.74M$1.75M$1.93M
Pretax income$205.12M$20.87M$79.65M$3.89M-$10.50M
Income tax$27.44M$6.86M-$11.30M$5.89M-$13.12M
Net income$177.69M$14.01M$90.95M-$2.00M$5.28M
EBITDA$206.72M$32.98M$100.81M$30.40M$8.91M
EPS (basic)4.570.362.37-0.050.14
EPS (diluted)4.520.362.32-0.050.14
Weighted avg. shares (diluted)39.29M39.27M39.22M37.84M37.88M
Balance sheet
Cash & equivalents$186.90M$324.40M$167.49M$69.86M$59.38M
Short-term investments$357.92M$15.73M$121.70M$118.17M$195.50M
Receivables$190.02M$167.67M$201.77M$203.38M$133.94M
Inventory$431.55M$406.74M$388.02M$334.01M$263.50M
Current assets$1.22B$951.12M$915.40M$755.70M$681.47M
PP&E, net$117.44M$62.64M$72.69M$65.02M$58.86M
Goodwill$166.75M$165.83M$166.27M$166.05M$166.39M
Intangibles$6.19M$6.51M$71.06M$81.16M$90.62M
Total assets$1.83B$1.53B$1.56B$1.37B$1.24B
Current liabilities$183.13M$158.34M$151.14M$144.93M$123.20M
Total liabilities$398.92M$382.25M$377.36M$372.03M$290.32M
Shareholders' equity$1.43B$1.15B$1.18B$998.86M$953.93M
Shares outstanding39.23M38.49M38.68M38.11M37.58M
Cash flow statement
Operating cash flow$238.66M$168.48M$97.33M-$55.66M$9.50M
Capital expenditure$63.73M$21.18M$15.21M$19.30M$21.18M
Free cash flow$174.93M$147.30M$82.12M-$74.96M-$11.68M
Investing cash flow-$404.59M$77.62M-$16.08M$54.79M-$21.73M
Financing cash flow$26.53M-$87.01M$16.20M$11.62M$836,000
Depreciation & amortization$17.47M$23.70M$27.26M$24.32M$16.41M
Stock-based compensation$59.21M$46.16M$50.52M$37.38M$65.76M
Share buybacks$0$100.39M$0$0—

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.